At the 2014 CMO Summit in Boston, Cytel's Jim Bolognese joins Ken Getz of Tuft's Center for the Study of Drug Development. Jim and Ken explore the rise in adaptive trials together with biomarker and simulation use in "Determining the Optimal Development Path".
Through case studies and dialog with session attendees, Jim and Ken address:
- How are biopharma developers making better early phase clinical strategy decisions with information from simulations and biomarkers?
- Is model-guided early phase development practical for smaller biotechs and specialty pharma companies?
- How common now are adaptive trials in early phase vs. Phase 3/pivotal trials?
Jim and Ken conclude by addressing questions from the audience of senior-level biopharma medical and science leadership..
www.cytel.com
+1 .617.661.2011
